Goldman Sachs’s Psyence Biomedical Warrant PBMWW Stock Holding History

Goldman Sachs’s Portfolio PBMWW Stock Details PBMWW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.86K	Hold	200,117	–	–	﹤0.01%	6497
2026 Q1	$3.64K	Hold	200,117	–	–	﹤0.01%	6407
2025 Q4	$3.71K	Hold	200,117	–	–	﹤0.01%	6389
2025 Q3	$5.04K	Hold	200,117	–	–	﹤0.01%	6275
2025 Q2	$4.06K	Hold	200,117	–	–	﹤0.01%	6030
2025 Q1	$3.38K	Hold	200,117	–	–	﹤0.01%	5998
2024 Q4	$2.88K	Hold	200,117	–	–	﹤0.01%	5969
2024 Q3	$2.52K	Hold	200,117	–	–	﹤0.01%	5760
2024 Q2	$2.1K	Buy	+200,117	New	+$11.1K	﹤0.01%	5600

Other funds holding PBMWW

HCI

Harraden Circle Investments New York $784M AUM 20.59% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TCM

Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

Goldman Sachs's PBMWW Position: Q2 2026 in Review

Goldman Sachs held its Psyence Biomedical Warrant (PBMWW) position steady in Q2 2026 at 200,117 shares worth $4.86K. The position accounts for ﹤0.01% of the portfolio, ranked #6497.

Goldman Sachs first reported a position in PBMWW in Q2 2024 and has held it in 9 quarters since. The position peaked at $5.04K in Q3 2025. 18 funds tracked by Wall St. Rank hold PBMWW as of Q2 2026.

Goldman Sachs held 200,117 shares of Psyence Biomedical Warrant worth $4.86K as of Q2 2026.
Goldman Sachs left its Psyence Biomedical Warrant share count unchanged in Q2 2026.
Psyence Biomedical Warrant made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6497 holding.
Goldman Sachs first reported a position in Psyence Biomedical Warrant in Q2 2024 and has held it in 9 quarters since.
Goldman Sachs's Psyence Biomedical Warrant position peaked at $5.04K in Q3 2025.
18 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.